October 2012- Volume 8, Issue 10

October 2012

In this Issue

Research & Development

A window into VISTA

A window into VISTA

Partnership aims to develop immunotherapies for cancer based on new negative checkpoint regulator

Acquisition elevates Sunovion’s respiratory focus

Acquisition elevates Sunovion’s respiratory focus

Company’s $100 million-plus purchase of Elevation Pharmaceuticals comes with novel nebulizer for COPD

Marching toward the front line

Marching toward the front line

SFJ and Pfizer to co-develop dacomitinib as first-line treatment for patients with advanced non-small cell lung cancer

Fixing broken hearts

Fixing broken hearts

University of Maryland cardiac studies explore use of stem cells to reduce ripple effect, help children

Court upholds federal hESC research funding

Court upholds federal hESC research funding

Plaintiff’s arguments in contentious Sherley v. Sebelius case rejected

Feature

Being human: ASHG 2012 annual meeting preview

Being human: ASHG 2012 annual meeting preview

American Society for Human Genetics delves into specifics of human genome in San Francisco

Tools & Technology

Filling a ‘critical’ gap

Filling a ‘critical’ gap

Agilent now offers single-vendor solutions in supercritical fluid chromatography with acquisition of Aurora SFC Systems’ assets

Leica Biosystems acquires Aperio

Leica Biosystems acquires Aperio

Aperio’s ePathology solutions key to the deal

Seeking growth with Molegro

Seeking growth with Molegro

CLC bio acquires Molegro, expands bioinformatics offering

No gene left behind

No gene left behind

PerkinElmer and Massachusetts General Hospital to develop a complete sequencing informatics system for cancer research

Global News

Adding mixtures to the mix

Adding mixtures to the mix

Merck, Symphogen ink $600 million-plus licensing deal for recombinant antibody for oncology

Going through a phage

Going through a phage

AmpliPhi to acquire Special Phage Services to create anti-infective company focused on bacteriophage-based therapies

Mad about mAbs

Mad about mAbs

Genmab licenses monoclonal antibody cancer treatment to Janssen Biotech in deal worth more than $1.1 billion

Give them a C

Give them a C

Medivir acquires preclinical antiviral programs from Novadex, including hepatitis C and prodrug technologies

Omics & Systems Biology

Treasure in the junk

Treasure in the junk

ENCODE project finds much less garbage in what has been called ‘junk DNA’

An infectious attitude

An infectious attitude

AstraZeneca, Broad Institute announce antibacterial, antiviral collaboration

Three partners, one target

Three partners, one target

Two British research organizations team with California-based pharma company to discover and develop novel blood cancer drug candidates

An alternative to liver transplantation

An alternative to liver transplantation

Collaboration between University of Cambridge and GSK seeks a breakthrough in A1AT deficiency treatment

Collaborators seek MS biomarkers

Collaborators seek MS biomarkers

Biogen Idec and Regulus Therapeutics to look for microRNAs as biomarkers for multiple sclerosis

Diagnostics

Intel inside Ivy

Intel inside Ivy

Stanford uses Intel chip to analyze protein interactions, diagnose disease

Paradigm for personalized medicine

Paradigm for personalized medicine

U-M/IGC joint venture uses genetic information to understand and treat disease

A picture-perfect focus

A picture-perfect focus

MacroGenics, ImaginAb collaboration to develop clinical imaging agents

Partners target ovarian cancer

Partners target ovarian cancer

Toronto biotech Axela and Calif.-based OvaGene Oncology develop molecular diagnostics test

PathGEN inks pact with Affymetrix

PathGEN inks pact with Affymetrix

Companies to tackle diagnostic test development for pathogen detection

Commentary

Barcodes in drug discovery: The quiet revolution

Barcodes in drug discovery: The quiet revolution

From the grocery store to the microwell plate in your lab, barcodes are ever-present. But our knowledge of them is often superficial, and as a result, we don’t fully enjoy their benefits. Their critical role in drug discovery suggests knowing how they work makes us more productive users of the technology.

Who needs R&D tax credits?

Who needs R&D tax credits?

No one with a brain makes an R&D decision based on tax credits. We make those decisions to try for a competitive advantage. If we don’t achieve that advantage, we shouldn’t expect to be partially reimbursed for the effort just to have our butts protected in a plea for fairness.

Editor's Focus

When the medium isn’t the message anymore

When the medium isn’t the message anymore

“Quotation approval” might have come into practice because sources wanted to ensure that their statements are correct and properly attributed, but unfortunately, this process often goes far beyond making sure a journalist recorded your statements accurately.

Special Reports

A companion in your corner (Part 1)

A companion in your corner (Part 1)

CDx market sees strong growth despite regulatory, development burdens

A companion in your corner (Part 2)

A companion in your corner (Part 2)

CDx market sees strong growth despite regulatory, development burdens

Contract Services

Charles River acquires Accugenix

Charles River acquires Accugenix

CRO expands microbial identification capabilities

A venture in the East

A venture in the East

MedImmune, WuXi AppTec announce joint venture to commercialize in China

From Ireland with love

From Ireland with love

ICON partners with University College Dublin to advance genetic analysis and clinical research
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

June 2023 Magazine Issue Front Cover

Latest Issue  

• Volume 19 • Issue 6 • June 2023

June 2023

June 2023 Issue